Cetermin

Drug Profile

Cetermin

Alternative Names: Betakine; Recombinant transforming growth factor-beta-2; TGF-beta-2; Transforming growth factor-beta-2

Latest Information Update: 15 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Insmed
  • Developer Enzon Pharmaceuticals; Genzyme Corporation; Insmed
  • Class Transforming growth factors
  • Mechanism of Action Immunosuppressants; Intercellular signalling peptide and protein stimulants; Osteogenesis stimulants; Transforming growth factor beta2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Age-related macular degeneration; Autoimmune disorders; Cancer; Diabetic foot ulcer; Eye-Disorders; Multiple sclerosis; Pleural effusion; Postmenopausal osteoporosis; Rheumatoid arthritis; Skin disorders; Transplant rejection

Most Recent Events

  • 10 Jan 2006 Discontinued - Phase-I for Multiple sclerosis in USA (IV)
  • 10 Jan 2006 Discontinued - Phase-II for Diabetic foot ulcer in USA (unspecified route)
  • 10 Jan 2006 Discontinued - Preclinical for Pleural effusion in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top